紫杉醇脂质体单药一线治疗老年晚期非小细胞肺癌的临床观察

目的 观察紫杉醇脂质体单药一线治疗老年晚期非小细胞肺癌（NSCLC）的近期疗效及不良反应。方法 21例经病理或细胞学确诊初治老年非小细胞肺癌患者，年龄≥65岁，KPS评分≥70分，其中19例合并程度不等的各种疾病。采用紫杉醇脂质体175mg/m2,静脉给药，每3周给药1次。2周期后评价疗效，观察近期疗效和化疗期间不良反应。结果 完全缓解(CR)0例，部分缓解（PR）5例(23.8%)，稳定（SD）10例(47.6%)，进展（PD）6例（28.6%）,有效率RR 23.8%，疾病控制率DCR为71.4%。主要不良反应为血液学毒性、胃肠道反应、肝功能损害,但均以Ⅰ、Ⅱ级为主。发生Ⅲ～Ⅳ级粒细胞减少为3例（14.2％），无感染与发热。无因化疗不良反应导致延迟或终止治疗，无化疗相关性死亡。结论 一般状况较好的老年晚期NSCLC患者采用紫杉醇脂质体单药化疗安全、有效，不良反应低，患者耐受性好。

Clinical Observation of Paclitaxel Liposome Single-agent on First-line Treatment in Elderly Patients with Advanced Non-small Cell Lung Cancer

Abstract:Objective To observe efficacy and side effects of Paclitaxel liposome single agent on the first line treatment of elderly patients with advanced non small cell lung cancer (NSCLC).Methods Twenty one elderly patients (age≥65 years, KPS≥70) with histologically or cytologically diagnosed advanced NSCLC were treated with Paclitaxel liposome (at a dose of 175mg／m2 day1 as a 3 h infusion on day 1，21days as one cycle)．The therapeutic efficacy was evaluated after 2 cycles of the chemotherapy.Results Among 21 patients all were evaluated for response and toxicity.The overall response rate was 23.8% with complete and partial response rate of 0.0% and 23.8%, respectively; the disease control rate was 71.4%.Adverse events were generally mild, mostly including myelo suppression, gastrointestinal and liver function impairment.There was no treatment related death.Conclusion The treatment of Paclitaxel liposome showed an effective antitumor activity and a favorable toxicity profile in elderly patientswith NSCLC.